Clearmind Medicine Receives U.S. Patent for Binge Behavior Treatment

Vancouver, Canada, Aug. 21, 2024 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0), a clinical-stage biotechnology firm, has announced the approval of a new patent by the United States Patent and Trademark Office. This development marks a significant milestone in the Company's MEAI-based binge behavior regulator program. The new patent encompasses methods for regulating alcohol consumption and managing binge behavior through the use of an amine aminoindane, specifically 5-methoxy-2-aminoindan (MEAI), which is the Company's innovative psychedelic compound.

This latest addition enhances Clearmind’s already extensive intellectual property portfolio in the psychedelic sector. The company now holds 29 granted patents across 19 patent families, with protections in critical regions including the U.S., Europe, China, and India. According to Dr. Adi Zuloff-Shani, CEO of Clearmind, the company is committed to leading in intellectual property protection in this field. Expanding and maintaining their patent portfolio, particularly in the U.S., is a primary objective. Dr. Zuloff-Shani emphasized that Clearmind aims to cover core areas such as MEAI, binge behavior, addictions, mental disorders, and new psychedelic compounds identified by their team.

MEAI is a novel psychoactive molecule designed to reduce the urge to consume alcoholic beverages while offering a mild euphoric, alcohol-like sensation. This compound has the potential to significantly improve the lives of millions who struggle with alcohol moderation. Clearmind’s flagship MEAI-based treatment targets Alcohol Use Disorder (AUD) and weight loss. AUD, a prevalent condition varying from mild to severe, is characterized by an individual's inability to control alcohol consumption despite negative social, occupational, or health consequences. Clearmind’s MEAI may also prove effective in treating binge drinking, a dangerous addiction that poses serious health risks.

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company that focuses on discovering and developing innovative psychedelic-derived therapeutics to address widespread and under-treated health problems, such as alcohol use disorder. The Company's main goal is to research and develop psychedelic-based compounds to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual property portfolio currently consists of 19 patent families, including 29 granted patents. Clearmind plans to seek additional patents for its compounds whenever necessary and remains open to acquiring more intellectual property to further build its portfolio. Shares of Clearmind are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under the symbol "CWY0." 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!